神经内分泌肿瘤一日双示踪剂检查:低活度长轴视野PET成像的实际优势
本研究纳入20例神经内分泌肿瘤患者,在长轴视野PET/CT上评估一日双示踪剂方案的可行性:先低活度[18F]FDG PET(0.5±0.01 MBq/kg),4.2±0.09小时后给予标准活度[18F]SiFAlin-TATE(3.0 MBq/kg)行SSTR-PET。模拟残留[18F]FDG活度仅占肿瘤病灶活度的极小比例,双示踪剂PET/CT结果直接影响11例(55%)患者的治疗计划。
要点
- 长轴视野PET支持一日内完成低活度[18F]FDG与[18F]SiFAlin-TATE双示踪剂PET/CT检查。
- 模拟残留[18F]FDG活度仅占第二次PET肿瘤病灶活度的5.2±0.9%(R15%)和6.8±1.2%(R20%)。
- 双示踪剂PET/CT结果直接改变了11例(55%)患者的治疗计划。
核心结论
- 长轴视野PET扫描仪使一日双示踪剂方案成为可能,在保持两种18F标记放射性示踪剂半定量的同时提供诊断图像质量,可能简化肿瘤生物学评估并改善临床患者管理,同时减少后勤挑战。
- 低活度PET成像促进了一日双示踪剂PET检查。
研究设计与样本
- 本研究纳入20例神经内分泌肿瘤患者,在长轴视野PET/CT扫描仪上评估一日双示踪剂方案的可行性。
- 先进行低活度[18F]FDG PET(0.5±0.01 MBq/kg;注射后60分钟扫描)。
- 完成[18F]FDG PET后4.2±0.09小时,给予标准活度[18F]SiFAlin-TATE(3.0 MBq/kg;注射后90分钟扫描)。
主要发现
- [18F]FDG脑摄取在后续SSTR-PET中显著降低([18F]FDG平均摄取SUVmean 6.0±0.4 vs [18F]SiFAlin-TATE PET平均摄取SUVmean 0.2±0.01,p<0.0001),心肌结果类似。
- 模拟残留[18F]FDG活度仅占第二次PET扫描肿瘤病灶活度的极小比例(R15%:均值5.2±0.9%;R20%:均值6.8±1.2%),提示[18F]FDG残留活度对[18F]SiFAlin-TATE第二次PET扫描的干扰极小,并保持了后者的半定量。
- 双示踪剂PET/CT结果直接影响11例(55%)受检患者的治疗计划改变。
关键数值与推荐
- 低活度[18F]FDG给药活度0.5±0.01 MBq/kg,注射后60分钟行PET扫描。
- 标准活度[18F]SiFAlin-TATE给药活度3.0 MBq/kg,注射后90分钟行PET扫描。
- 模拟残留[18F]FDG最大残留活度15%(R15%)和20%(R20%)分别对应肿瘤病灶活度的均值5.2±0.9%和6.8±1.2%。
临床怎么用
- 原文未据此给出推荐。
- 作者结论指出长轴视野PET扫描仪使一日双示踪剂方案成为可能,可能简化肿瘤生物学评估并改善临床患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Somatostatin receptor (SSTR)-PET is crucial for effective treatment stratification of neuroendocrine neoplasms (NENs). In highly proliferating or poorly differentiated NENs, dual-tracer approaches using additional [18F]FDG PET can effectively identify SSTR-negative disease, usually requiring separate imaging sessions. We evaluated the feasibility of a one-day dual-tracer imaging protocol with a low activity [18F]FDG PET followed by an SSTR-PET using the recently introduced [18F]SiFAlin-TATE tracer in a long axial field-of-view (LAFOV) PET/CT scanner and its implications in patient management. METHODS: Twenty NEN patients were included in this study. Initially, a low activity [18F]FDG PET was performed (0.5 ± 0.01 MBq/kg; PET scan 60 min p.i.). After 4.2 ± 0.09 h after completion of the [18F]FDG PET, a standard activity of [18F]SiFAlin-TATE was administered (3.0 MBq/kg; PET scan 90 min p.i.). To ensure the quantification accuracy of the second scan, we evaluated the potential impact of residual [18F]FDG activity by segmenting organs with minimal physiological SSTR-tracer uptake, such as the brain and myocardium, and assessing the activity concentrations (ACTs) of tumor lesions. Residual tumor lesion ACTs of [18F]FDG were calculated by factoring fluorine-18 decay, identifying a maximum residual ACT of 15% (R15%). To account for increased [18F]FDG trapping over time, higher residual ACTs of 20% (R20%) were considered. These simulated [18F]FDG ACTs were compared with those measured in the second PET scan with [18F]SiFAlin-TATE. The influence of the dual-tracer PET/CT results on therapeutic strategies was evaluated. RESULTS: [18F]FDG cerebral uptake significantly decreased in the subsequent SSTR-PET (mean uptake [18F]FDG: SUVmean 6.0 ± 0.4; mean uptake in [18F]SiFAlin-TATE PET: SUVmean 0.2 ± 0.01; p < 0.0001); with similar results recorded for the myocardium. Simulated residual [18F]FDG ACTs represented only a minimal percentage of ACTs measured in the tumor lesions from the second PET scan (R15%: mean 5.2 ± 0.9% and R20%: mean 6.8 ± 1.2%), indicating only minimal residual activity of [18F]FDG that might interfere with the second PET scan using [18F]SiFAlin-TATE and preserved semi-quantification of the latter. Dual-tracer PET/CT findings directly influenced changes in therapy plans in eleven (55%) of the examined patients. CONCLUSION: LAFOV PET scanners enable a one-day dual-tracer protocol, providing diagnostic image quality while preserving the semi-quantification of two 18F-labeled radiotracers, potentially simplifying the assessment of tumor biology and improving the clinical patient management while reducing logistical challenges. Additionally, low-activity PET imaging facilitates one-day dual-tracer PET examinations.
引用
- Calderón E, Kiefer LS, Schmidt FP, et al. One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 39883139. doi:10.1007/s00259-025-07073-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。